Merus to Present at the Jefferies 2019 Healthcare Conference
UTRECHT, Netherlands, June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President, Chief Executive Officer and Principal Financial Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019, at 10:00 a.m. ET.
A live webcast of the event will be available on the Investors and Media page of the Company's website, http://www.merus.nl. A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information on the company and programs, please visit Merus’ website, www.merus.nl .
Investor and Media Inquiries:
Investor Relations and Corporate Communications
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TDC A/S3.9.2019 12:51:36 CEST | Press release
TDC A/S and DKT Holdings ApS: Updated financial calendar for 2019
Jobindex A/S20.8.2019 08:42:29 CEST | Pressemeddelelse
2. kvartal 2019: Væksten på jobmarkedet er gået i stå
Bizagi17.7.2019 18:02:02 CEST | Press release
Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands
Erytech Pharma S.A.16.7.2019 22:02:00 CEST | Press release
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
WSO215.7.2019 15:02:38 CEST | Press release
WSO2 Introduces WSO2 API Microgateway 3.0 to Simplify Creating, Deploying and Securing APIs in Microservice Environments
Lubrizol15.7.2019 08:01:33 CEST | Press release
Lubrizol Acquires Bavaria Medizin Technologie GmbH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom